HAISHUN(SZ:300501)2025-04-17 11:05Dividend Distribution - The company plans to distribute a cash dividend of 2.7 CNY per 10 shares (including tax) to all shareholders, with no bonus shares issued[3]. - The company plans to distribute a cash dividend of RMB 2.7 per 10 shares (including tax) for the first three quarters of 2024, with a total dividend amounting to RMB 50,850,235.62 (including tax) based on a total share capital of 193,537,806 shares as of September 30, 2024[165]. - The actual cash dividend distributed for the fiscal year 2023 was RMB 28,660,530.90 (including tax), calculated from a total share capital of 193,531,895 shares after accounting for repurchased shares[164]. - The company has not issued any bonus shares or capital reserves for the current fiscal year, and the remaining undistributed profits will be carried forward to the next fiscal year[167]. Financial Performance - The company's operating revenue for 2024 was ¥1,142,549,822.03, representing an increase of 11.92% compared to ¥1,020,872,006.74 in 2023[17]. - The net profit attributable to shareholders for 2024 decreased by 12.70% to ¥74,589,975.03 from ¥85,441,741.28 in 2023[17]. - The cash flow from operating activities increased significantly by 60.35% to ¥161,307,846.86 in 2024, compared to ¥100,596,592.11 in 2023[17]. - The basic earnings per share for 2024 was ¥0.39, down 11.36% from ¥0.44 in 2023[17]. - The total assets at the end of 2024 were ¥2,885,699,417.44, a decrease of 3.38% from ¥2,986,593,236.85 at the end of 2023[17]. - The company reported a net profit of ¥4,974,701.38 from non-recurring gains and losses in 2024, down from ¥16,997,149.67 in 2023[23]. - In 2024, the company achieved a revenue of 1.143 billion yuan, representing a year-on-year growth of 11.92%[43]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 69.6153 million yuan, an increase of 1.71% year-on-year[43]. Market and Industry Trends - The global pharmaceutical packaging market is projected to grow from $134.18 billion in 2024 to $180 billion by 2029, with a CAGR of approximately 6.2%[26]. - The domestic pharmaceutical packaging materials sub-industry is expected to see a revenue growth rate of 3% in 2024, driven by stable market demand and policy support[26]. - The pharmaceutical packaging industry is experiencing increased concentration due to high technical and capital requirements, leading to the elimination or acquisition of smaller companies unable to adapt to industry trends[28]. - The demand for pharmaceutical packaging materials is directly linked to drug consumption, exhibiting weak cyclical characteristics as pharmaceuticals are essential consumer goods[28]. Research and Development - The company reported a significant focus on research and development of new drug packaging materials to enhance market competitiveness[3]. - The company's R&D investment reached 52.32 million yuan in 2024, marking a 3.91% increase compared to the previous year[43]. - The company is focusing on developing recyclable and biodegradable materials to contribute to the industry's green development[27]. - The company is developing a new anti-counterfeiting cold-pressed aluminum composite sheet, currently in the small batch trial production phase[61]. - The company is also working on a high-barrier liquid packaging film and its packaging bags, aimed at extending the shelf life of liquid medicines[61]. - The company is developing a lightweight cold-pressed aluminum composite sheet with a thickness of 140-160um, aiming to improve barrier performance while reducing weight[62]. Operational Efficiency - The company has established a robust financial reporting framework to ensure transparency and accuracy in its financial disclosures[3]. - The company utilizes an ERP system for production management, ensuring efficiency and quality control throughout the manufacturing process[37]. - The company has developed a digital management system across the entire supply chain to enhance operational efficiency and reduce production costs[42]. - The company has implemented a talent incentive mechanism to retain key personnel, ensuring that their expertise and experience contribute to the company's competitive edge[121]. Compliance and Governance - The company emphasizes the importance of maintaining compliance with Good Manufacturing Practices (GMP) to ensure product quality and safety[11]. - The company has established a comprehensive quality management system, achieving multiple certifications including ISO13485 and FSSC22000[46]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, and operations[135]. - The company has engaged professional lawyers to ensure compliance during shareholder meetings[130]. - The company’s governance practices align with the regulations set forth by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[134]. Environmental Responsibility - The company complies with various environmental protection laws and standards, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[179]. - The company is listed as a key regulatory unit for environmental risk control by the Zhejiang Provincial Ecological Environment Department and the Suzhou Ecological Environment Bureau[178]. - The company has obtained pollution discharge permits for its subsidiaries, with validity periods extending to 2029[180]. - The company conducts internal inspections and external testing to ensure compliance with pollution discharge standards[181]. Strategic Investments - The company plans to invest 4,675 million RMB in Zhejiang Duoling Pharmaceutical Packaging Materials Co., increasing its stake to 68% and enhancing production capacity to 1,500 tons of high-barrier pharmaceutical packaging composite film annually[106]. - The company has made a strategic investment of 21,507.5 million RMB to acquire a 43.015% stake in Shanghai Jiucheng Packaging Co., enhancing its presence in the fast-moving consumer goods packaging sector[107]. - The company is focusing on expanding its market presence through strategic investments and partnerships[78]. Employee Engagement and Development - The total number of employees at the end of the reporting period is 1,018, with 645 in production, 119 in sales, 136 in technology, 29 in finance, and 89 in administration[160][161]. - The company emphasizes employee training and development, planning to enhance its high-level talent training system by 2025 to improve employee professional skills and service levels[163]. - The company has established a competitive salary management system, with performance-based salary adjustments and annual performance bonuses linked to individual and company performance[162]. Risk Management - The company faces various risks including market competition, raw material price fluctuations, and potential declines in gross margin[3]. - The company faces risks from raw material price fluctuations, with significant cost contributions from aluminum foil and plastic particles, which are influenced by macroeconomic conditions and supply-demand dynamics[118]. - To mitigate raw material price risks, the company has established long-term relationships with multiple suppliers and employs a cost transmission mechanism to adjust product pricing accordingly[118]. - The company is addressing capacity digestion risks by closely monitoring market dynamics and optimizing production processes to maintain high capacity utilization rates[119].